KR20100098396A - ４（­３­（­２­（페닐）모르폴리노）­２­옥소피롤리딘­１­일)­ｎ­（티아졸­２­일）벤젠설폰아미드 유도체, 및 통증 치료를 위한 이온 채널의 조절제로서의 관련 화합물 - Google Patents

４（­３­（­２­（페닐）모르폴리노）­２­옥소피롤리딘­１­일)­ｎ­（티아졸­２­일）벤젠설폰아미드 유도체, 및 통증 치료를 위한 이온 채널의 조절제로서의 관련 화합물 Download PDF

Info

Publication number
KR20100098396A
KR20100098396A KR1020107012968A KR20107012968A KR20100098396A KR 20100098396 A KR20100098396 A KR 20100098396A KR 1020107012968 A KR1020107012968 A KR 1020107012968A KR 20107012968 A KR20107012968 A KR 20107012968A KR 20100098396 A KR20100098396 A KR 20100098396A
Authority
KR
South Korea
Prior art keywords
pain
compound
aliphatic
mmol
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107012968A
Other languages
English (en)
Korean (ko)
Inventor
딘 스테이모스
에스더 마틴보로우
티모시 노이베르트
메흐디 미쉘 자멜 누마
타라 휘트니
니콜 짐머만
아르티 사미르 카왓카르
Original Assignee
버텍스 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버텍스 파마슈티칼스 인코포레이티드 filed Critical 버텍스 파마슈티칼스 인코포레이티드
Publication of KR20100098396A publication Critical patent/KR20100098396A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020107012968A 2007-11-13 2008-11-12 ４（­３­（­２­（페닐）모르폴리노）­２­옥소피롤리딘­１­일)­ｎ­（티아졸­２­일）벤젠설폰아미드 유도체, 및 통증 치료를 위한 이온 채널의 조절제로서의 관련 화합물 Withdrawn KR20100098396A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98748507P 2007-11-13 2007-11-13
US60/987,485 2007-11-13
US8814108P 2008-08-12 2008-08-12
US61/088,141 2008-08-12

Publications (1)

Publication Number Publication Date
KR20100098396A true KR20100098396A (ko) 2010-09-06

Family

ID=40380263

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107012968A Withdrawn KR20100098396A (ko) 2007-11-13 2008-11-12 ４（­３­（­２­（페닐）모르폴리노）­２­옥소피롤리딘­１­일)­ｎ­（티아졸­２­일）벤젠설폰아미드 유도체, 및 통증 치료를 위한 이온 채널의 조절제로서의 관련 화합물

Country Status (13)

Country Link
US (3) US7994166B2 (https=)
EP (1) EP2231655B1 (https=)
JP (1) JP2011503112A (https=)
KR (1) KR20100098396A (https=)
CN (1) CN102036985A (https=)
AT (1) ATE522526T1 (https=)
AU (1) AU2008321137A1 (https=)
CA (1) CA2705336A1 (https=)
IL (1) IL205697A0 (https=)
MX (1) MX2010005309A (https=)
NZ (1) NZ585332A (https=)
RU (1) RU2010123781A (https=)
WO (1) WO2009064747A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
CA2608599A1 (en) * 2005-05-16 2006-11-23 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
MX2008003337A (es) * 2005-09-09 2008-09-26 Vertex Pharma Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
CN101331115A (zh) * 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
MX2009012678A (es) 2007-05-25 2012-09-20 Vertex Pharma Moduladores de canal de ion y metodos de uso.
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
US7994166B2 (en) 2007-11-13 2011-08-09 Vertex Pharmaceuticals Incorporated Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain
WO2009064752A2 (en) * 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2010002956A2 (en) * 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
NZ627259A (en) * 2012-01-16 2016-12-23 Vertex Pharma Pyran-spirocyclic piperidine amides as modulators of ion channels
MX2015004371A (es) 2012-10-12 2015-07-06 Hoffmann La Roche Compuestos de fenilcarbamato sustituidos.
WO2014060341A1 (en) 2012-10-16 2014-04-24 F. Hoffmann-La Roche Ag Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
US10968210B2 (en) 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
ES2946917T3 (es) 2017-07-21 2023-07-27 Antabio Sas Compuestos químicos
CN113008999B (zh) * 2019-12-19 2024-08-23 重庆药友制药有限责任公司 一种分离测定氟比洛芬酯中2种基因毒性杂质的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO2004103980A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
JP2007261945A (ja) * 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
MX2007014180A (es) * 2005-05-10 2008-01-14 Vertex Pharma Derivados biciclicos como moduladores de canales de iones.
CA2608599A1 (en) * 2005-05-16 2006-11-23 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
EP1891039A1 (en) 2005-05-20 2008-02-27 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
MX2007015726A (es) * 2005-06-09 2008-03-04 Vertex Pharma Derivados de indano como moduladores de canales ionicos.
MX2008003337A (es) * 2005-09-09 2008-09-26 Vertex Pharma Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
EP1934191B1 (en) 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Biphenyl derivatives as modulators of voltage gated ion channels
CN101331115A (zh) * 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
EP2316829A1 (en) * 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
MX2009012678A (es) 2007-05-25 2012-09-20 Vertex Pharma Moduladores de canal de ion y metodos de uso.
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
US7994166B2 (en) 2007-11-13 2011-08-09 Vertex Pharmaceuticals Incorporated Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain
WO2009064752A2 (en) * 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2010002956A2 (en) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels

Also Published As

Publication number Publication date
ATE522526T1 (de) 2011-09-15
WO2009064747A3 (en) 2010-08-19
EP2231655B1 (en) 2011-08-31
IL205697A0 (en) 2010-11-30
WO2009064747A2 (en) 2009-05-22
RU2010123781A (ru) 2011-12-20
AU2008321137A1 (en) 2009-05-22
JP2011503112A (ja) 2011-01-27
US20130338119A1 (en) 2013-12-19
CN102036985A (zh) 2011-04-27
US20090131440A1 (en) 2009-05-21
US8841282B2 (en) 2014-09-23
MX2010005309A (es) 2010-06-25
US20120010416A1 (en) 2012-01-12
EP2231655A2 (en) 2010-09-29
NZ585332A (en) 2012-05-25
CA2705336A1 (en) 2009-05-22
US7994166B2 (en) 2011-08-09

Similar Documents

Publication Publication Date Title
EP2231655B1 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain
US8343763B2 (en) Heterocyclic derivatives as modulators of ion channels
KR20080015102A (ko) 이온 채널 조절인자로서의 바이사이클릭 유도체
US8097636B2 (en) Heterocyclic derivatives as modulators of ion channels
KR20080109918A (ko) 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
KR20080081178A (ko) 이온 채널 조절인자로서의 헤테로사이클릭 유도체
JP2010539244A (ja) イオンチャネルのモジュレーターとしてのピリジルスルホンアミド
KR20080021030A (ko) 이온 채널 조절인자로서의 바이사이클릭 유도체
KR20080019693A (ko) 이온 채널 조절인자로서의 인단 유도체
KR20080059292A (ko) 전압 개폐 이온 채널 조절인자로서의 바이페닐 유도체
KR20080044910A (ko) 전압 개폐 이온 채널 조절인자로서의 바이사이클릭 유도체
ES2371802T3 (es) Derivados de 4(-3-(2-(fenil)morfolino)-2-osopirrolidín-1-il)-n-(tiazol-2-il)bencenosulfonamida y compuestos relacionados como moduladores de canales de iones para el tratamiento de dolor.
HK1152298A (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin derivati ves and related compounds as modulators of ion channels for the treatment of pain
HK1146268A (en) Heterocyclic derivatives as modulators of ion channels

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100611

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid